Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Crinetics Pharmaceuticals’s 10-K, filed February 26, 2026.
- Filed
- Feb 26, 2026, 4:25 PM EST
- Fiscal year
- FY2025
- Accession
- 0001658247-26-000012
| Line item | Year ended December 31, 2025 | Year ended December 31, 2024 | Year ended December 31, 2023 |
|---|---|---|---|
| Operating expenses: | |||
| Cost of product revenue | 1,076 | — | — |
| Research and development | 332,058 | 240,156 | 168,527 |
| Selling, general and administrative | 191,331 | 99,737 | 58,094 |
| Total operating expenses | 524,465 | 339,893 | 226,621 |
| Loss from operations | (516,769) | (338,854) | (222,608) |
| Other income (expense): | |||
| Interest income | 51,989 | 41,435 | 13,436 |
Item 16. Form 10-K Summary
FAQ
- What is Crinetics Pharmaceuticals's SG&A?
- Crinetics Pharmaceuticals (CRNX) reported SG&A of $47.83M in Q4 2025.
- How has Crinetics Pharmaceuticals's SG&A changed year-over-year?
- Crinetics Pharmaceuticals's SG&A increased by 91.8% year-over-year, from $24.93M to $47.83M.
- What is the long-term trend for Crinetics Pharmaceuticals's SG&A?
- Over 2 years (2023 to 2025), Crinetics Pharmaceuticals's SG&A has grown at a 81.5% compound annual growth rate (CAGR), from $58.09M to $191.33M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Crinetics Pharmaceuticals's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude